Last reviewed · How we verify
low-volume PEG -ascorbic acid
At a glance
| Generic name | low-volume PEG -ascorbic acid |
|---|---|
| Also known as | Moviprep, Norgine Ltd, Harefield, UK |
| Sponsor | ASST Fatebenefratelli Sacco |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- PEG-Asc Vs. SPMC for Bowel Preparation in Capsule-based Procedures (NA)
- Efficacy And Tolerability Of Asymmetric Split Regimen For Bowel Preparation (NA)
- Effect of Low-volume (1L) vs Intermediate-volume (2L) Bowel Preparation on Cost-effectiveness and Quality of Life (NA)
- Polyethylene Glycol Versus Low Volume Solutions Prior to Colonoscopy (PHASE4)
- Impact of a Predictive Score of Bowel Preparation Quality in Clinical Practice (PHASE4)
- Tolerability and Efficacy of Sodium Picosulfate/Magnesium Citrate Versus PEG/Ascorbic Acid in Ulcerative Colitis Patients (PHASE4)
- Comparison of Different Low Volume Solutions Prior to Colonoscopy (PHASE4)
- Individualized Bowel Preparation for Colonoscopy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- low-volume PEG -ascorbic acid CI brief — competitive landscape report
- low-volume PEG -ascorbic acid updates RSS · CI watch RSS
- ASST Fatebenefratelli Sacco portfolio CI